Sonalika Khachikian, MD
Endocrinology, Diabetes & Metabolism · Rapid City, SDNPI 1699934067
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $248,397 of the $364,579 with a category attached, or 68.1%. Amgen accounts for 89.2% of it on its own, with 31 other manufacturers making up the rest. Among endocrinology, diabetes & metabolism clinicians in SD with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 770 payments — averaging $473.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$325K
- Johnson & Johnson$33K
- Novo Nordisk$3K
- Dexcom, Inc.$1K
- Medtronic$490
- Lilly USA, LLC$428
- plus $2K from 26 others
Across 14 payments — averaging $10,366 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$145K
What the payments were for
- Consulting fees$49,49514%
- Speaking & faculty fees$248,39768%
- Travel & lodging$52,42014%
- Food & beverage$14,2464%
- Education$210%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 387 | $325,027 |
| Johnson & Johnson | 159 | $32,886 |
| Novo Nordisk | 73 | $2,786 |
| Dexcom, Inc. | 37 | $1,192 |
| Medtronic(2 entities) | 11 | $490 |
| Lilly USA, LLC | 37 | $428 |
| AstraZeneca(2 entities) | 10 | $257 |
| Sanofi-aventis U.S. LLC | 9 | $247 |
| Bayer | 5 | $189 |
| Ascendis Pharma Endocrinology Inc | 4 | $181 |
| Tandem Diabetes Care, Inc. | 3 | $155 |
| Abbott | 3 | $107 |
| Novartis | 5 | $83 |
| Boehringer Ingelheim | 4 | $61 |
| UCB, Inc. | 1 | $59 |
| Boston Scientific | 1 | $56 |
| Pfizer | 3 | $52 |
| Nevro Corp. | 1 | $38 |
| Mallinckrodt Enterprises LLC | 2 | $31 |
| Janssen Scientific Affairs, LLC | 1 | $27 |
| Companion Medical, Inc. | 1 | $26 |
| Shire North American Group Inc | 2 | $26 |
| BD | 1 | $25 |
| Recordati_rare_diseases_inc. | 1 | $22 |
| Actelion Pharmaceuticals US, Inc. | 2 | $21 |
| Corcept Therapeutics | 1 | $20 |
| AbbVie | 1 | $17 |
| Neurocrine Biosciences, Inc. | 1 | $16 |
| Madrigal Pharmaceuticals | 1 | $16 |
| Rhythm Pharmaceuticals, Inc. | 1 | $15 |
| Sanofi | 1 | $13 |
| Clarus Therapeutics Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TEPEZZA$270,757
- INVOKANA$31,782
- EVENITY$29,384
- UPLIZNA$7,150
- RYBELSUS$1,745
- Minimed 630G$140
- DEXCOM CGM$129
- SOLIQUA 100/33$125
- Kerendia$125
- Yorvipath$121
- FARXIGA$115
- Prolia$102
How this compares
$364,579 in reported general payments places this provider in the 90th percentile of 20 endocrinology, diabetes & metabolism providers in South Dakota.
See all endocrinology, diabetes & metabolism providers in South Dakota →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 365 | $505,929 |
| JardianceEmpagliflozin | 201 | $223,236 |
| MounjaroTirzepatide | 66 | $96,159 |
| Tresiba Flextouch U-200Insulin Degludec | 73 | $83,882 |
| FarxigaDapagliflozin Propanediol | 84 | $80,651 |
| TrulicityDulaglutide | 28 | $56,600 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 44 | $56,057 |
| Tresiba Flextouch U-100Insulin Degludec | 84 | $44,747 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 44 | $44,606 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 29 | $38,544 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 37 | $28,212 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 46 | $26,573 |
| InvokanaCanagliflozin | 26 | $25,892 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 24 | $22,812 |
| Novolog FlexpenInsulin Aspart | 93 | $22,543 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog | $2,786 | $510,514380 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $61 | $251,448238 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $428 | $161,123115 claims |
| AstraZenecaFarxiga | $257 | $80,65184 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $247 | $60,47161 claims |
| Johnson & JohnsonInvokana | $32,886 | $25,89226 claims |
| AbbVieSynthroid, Armour Thyroid | $17 | $24,987339 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 20 endocrinology, diabetes & metabolism providers in South Dakota.
Other endocrinology, diabetes & metabolism in Rapid City
- John PalmerRapid City$419K
- Melanie RayanRapid City$451
- Richard CrawfordSioux Falls$126K
- Brandon AllardSioux Falls$3K
- Randall FennerSioux Falls$2K
- Marie Angelica DiazSioux Falls$2K
- Hassan MehmoodSioux Falls$1K
- Lorayne ChuaSioux Falls$1K
- Marcio GriebelerSioux Falls$1K
- Anthony SallarSioux Falls$921
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.